AstraZeneca’s (AZN) camizestrant, branded Etcamah, has failed to demonstrate a statistically significant improvement in a major Phase III breast cancer trial, dealing a blow to the drug’s broader commercial ambitions.
The SERENA-4 study compared Etcamah plus palbociclib against anastrozole plus palbociclib in patients with previously untreated ER-positive, HER2-negative advanced breast cancer.
The trial enrolled 1,371 adults who had received no prior systemic treatment for advanced disease, making it one of the larger studies in the oral SERD space.
Although investigators recorded a numerical improvement in progression-free survival favouring the Etcamah combination, the trial did not meet statistical significance on its primary endpoint.
The failure specifically impacts the drug’s potential in the broader first-line treatment market, where a successful result would have opened up a significantly wider patient population for AstraZeneca.
The setback arrives just days after a notable regulatory milestone, as the US Food and Drug Administration granted Etcamah accelerated approval on September 4 for patients with advanced breast cancer harbouring emerging ESR1 mutations, based on the separate SERENA-6 study.
The distinction between the two trials is clinically important, with SERENA-6 identifying resistance as it emerges through ESR1 mutation testing and switching therapy proactively, while SERENA-4 attempted to establish Etcamah as an upfront replacement for aromatase inhibitors.
The SERENA-4 result suggests Etcamah’s benefit may be concentrated in tumours with a detectable resistance mechanism rather than across the broader untreated first-line population.
AstraZeneca is not alone in struggling with first-line oral SERD trials, as Roche’s giredestrant also recently failed in first-line HR-positive, HER2-negative breast cancer, raising questions about the entire drug class in this setting.
Giredestrant had previously contributed to a downturn in enthusiasm around oral SERDs in 2022, when it failed a midphase test and Sanofi’s rival asset amcenestrant also flunked a pivotal trial.
The SERENA-4 failure raises the evidence bar for AstraZeneca’s two additional Phase III studies in earlier breast cancer settings, CAMBRIA-1 and CAMBRIA-2, which together form part of a development programme involving roughly 10,000 patients.
Investors reacted swiftly to the SERENA-4 announcement, with AstraZeneca’s US-listed shares declining by approximately 3% during after-hours trading on September 11.
The broader lesson from SERENA-4 may ultimately point toward precision timing rather than universal treatment escalation, with tumour biology guiding when patients switch to next-generation endocrine therapy.